News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
|Articles|September 22, 2015

Jenna Earl

Author(s)Jenna Earl
Advertisement

Jenna Ealr is Senior Consultant at Blue Latitude

http://bluelatitude.net/about-us-strategic-marketing-consultants/jenna/

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
President Donald Trump

Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan

ByNicholas Jacobus
January 9th 2026
Stock.adobe.com

Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026

ByNicholas Jacobus
January 9th 2026
Angela Schwab

Can AI Help Solve the Issue of High Failure Rates in Clinical Trials?

ByMike Hollan,Angela Schwab
January 9th 2026

The Situation We Faced: Aaron Cowley, CSO, Recipharm Advanced Bio, Discusses Vision to Cut Biomanufacturing Timelines, Transform Continuous Manufacturing

ByChris Spivey,Aaron Cowley
January 8th 2026
Image Credit: Adobe Stock Images/KRISTINA KUPTSEVICH

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

ByDavy James
January 8th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

2

Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan

3

Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026

4

Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences

5

Can AI Help Solve the Issue of High Failure Rates in Clinical Trials?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us